Drug intelligence / Profile preview

CSI-102

Development stage
Preclinical
Lead developer
Curigin
Modality
Gene Therapies, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Parenteral
01

Overview

CSI-102 (also known as Csi102 or Csi-102) is a preclinical-stage gene therapy candidate being developed by Curigin for the treatment of hepatitis B. Utilizing Curigin's proprietary bi-specific siRNA platform, CSI-102 is designed to simultaneously target and inhibit the expression of both the hepatitis B virus (HBV) core protein and interleukin-6 (IL-6). The therapeutic payload is delivered via a viral vector (adenovirus) to achieve dual-gene silencing, aiming to suppress viral replication while mitigating the inflammatory response associated with chronic HBV infection.

Other names
Csi 102Csi102Csi-102
02

Targets

Hepatitis B virus core messenger RNAHBc (Hepatitis B virus core protein)IL-6 (Interleukin 6)

Beyond the preview

Go deeper on CSI-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CSI-102.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call